Akari Therapeutics Files 8-K on Financials
Ticker: AKTX · Form: 8-K · Filed: May 15, 2025 · CIK: 1541157
Sentiment: neutral
Topics: financial-reporting, company-update
Related Tickers: AKTX
TL;DR
Akari Therapeutics dropped an 8-K on May 15th detailing their financial condition and results.
AI Summary
Akari Therapeutics Plc filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company, previously known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC, is incorporated in England and Wales and has its principal executive offices in Boston, MA.
Why It Matters
This filing provides crucial updates on Akari Therapeutics' financial health and operational results, which are essential for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not contain new material events or risks.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- Celsus Therapeutics Plc (company) — Former company name
- Morria Biopharmaceuticals PLC (company) — Former company name
- May 15, 2025 (date) — Date of report
- 22 Boston Wharf Road FL 7 Boston, MA 02210 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Akari Therapeutics Plc's results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on May 15, 2025.
What were Akari Therapeutics Plc's previous names?
Akari Therapeutics Plc was formerly known as Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC.
Where are Akari Therapeutics Plc's principal executive offices located?
Akari Therapeutics Plc's principal executive offices are located at 22 Boston Wharf Road, FL 7, Boston, MA 02210.
What is the Standard Industrial Classification code for Akari Therapeutics Plc?
The Standard Industrial Classification code for Akari Therapeutics Plc is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 15, 2025 regarding Akari Therapeutics Plc (AKTX).